Zimmer Biomet Holdings Debt to Equity Ratio 2006-2018 | ZBH
Current and historical debt to equity ratio values for Zimmer Biomet Holdings (ZBH) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Zimmer Biomet Holdings debt/equity for the three months ending December 31, 2018 was 0.75.
| Zimmer Biomet Holdings Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2018-12-31 | $8.44B | $0.00B | 0.00 |
| 2018-09-30 | $8.60B | $12.22B | 0.70 |
| 2018-06-30 | $9.41B | $12.04B | 0.78 |
| 2018-03-31 | $9.49B | $12.00B | 0.79 |
| 2017-12-31 | $8.92B | $11.74B | 0.76 |
| 2017-09-30 | $9.20B | $10.45B | 0.88 |
| 2017-06-30 | $9.35B | $10.28B | 0.91 |
| 2017-03-31 | $10.54B | $9.93B | 1.06 |
| 2016-12-31 | $10.67B | $9.67B | 1.10 |
| 2016-09-30 | $11.01B | $9.75B | 1.13 |
| 2016-06-30 | $10.53B | $9.55B | 1.10 |
| 2016-03-31 | $11.12B | $9.66B | 1.15 |
| 2015-12-31 | $11.50B | $9.89B | 1.16 |
| 2015-09-30 | $11.69B | $9.99B | 1.17 |
| 2015-06-30 | $11.75B | $10.13B | 1.16 |
| 2015-03-31 | $9.06B | $6.58B | 1.38 |
| 2014-12-31 | $1.43B | $6.55B | 0.22 |
| 2014-09-30 | $1.43B | $6.54B | 0.22 |
| 2014-06-30 | $1.69B | $6.45B | 0.26 |
| 2014-03-31 | $1.68B | $6.24B | 0.27 |
| 2013-12-31 | $1.67B | $6.30B | 0.27 |
| 2013-09-30 | $1.69B | $6.14B | 0.28 |
| 2013-06-30 | $1.69B | $5.89B | 0.29 |
| 2013-03-31 | $1.70B | $5.71B | 0.30 |
| 2012-12-31 | $1.72B | $5.87B | 0.29 |
| 2012-09-30 | $1.73B | $5.83B | 0.30 |
| 2012-06-30 | $1.73B | $5.71B | 0.30 |
| 2012-03-31 | $1.57B | $5.66B | 0.28 |
| 2011-12-31 | $1.58B | $5.52B | 0.29 |
| 2011-09-30 | $1.54B | $5.61B | 0.28 |
| 2011-06-30 | $1.15B | $6.02B | 0.19 |
| 2011-03-31 | $1.14B | $5.86B | 0.19 |
| 2010-12-31 | $1.14B | $5.77B | 0.20 |
| 2010-09-30 | $1.14B | $5.82B | 0.20 |
| 2010-06-30 | $1.13B | $5.74B | 0.20 |
| 2010-03-31 | $1.13B | $5.71B | 0.20 |
| 2009-12-31 | $1.13B | $5.64B | 0.20 |
| 2009-09-30 | $0.60B | $5.98B | 0.10 |
| 2009-06-30 | $0.65B | $5.81B | 0.11 |
| 2009-03-31 | $0.66B | $5.56B | 0.12 |
| 2008-12-31 | $0.46B | $5.65B | 0.08 |
| 2008-09-30 | $0.33B | $5.62B | 0.06 |
| 2008-06-30 | $0.33B | $5.51B | 0.06 |
| 2008-03-31 | $0.12B | $5.71B | 0.02 |
| 2007-12-31 | $0.10B | $5.45B | 0.02 |
| 2007-09-30 | $0.10B | $5.25B | 0.02 |
| 2007-06-30 | $0.10B | $5.28B | 0.02 |
| 2007-03-31 | $0.10B | $5.12B | 0.02 |
| 2006-12-31 | $0.10B | $4.92B | 0.02 |
| 2006-09-30 | $0.10B | $4.80B | 0.02 |
| 2006-06-30 | $0.08B | $4.90B | 0.02 |
| 2006-03-31 | $0.08B | $4.92B | 0.02 |
| 2005-12-31 | $0.08B | $4.68B | 0.02 |
| 2005-09-30 | $0.09B | $4.51B | 0.02 |
| 2005-06-30 | $0.27B | $4.31B | 0.06 |
| 2005-03-31 | $0.43B | $4.15B | 0.10 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $25.289B | $7.933B |
| Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. Zimmer Biomet Holdings, Inc., formerly known as Zimmer Holdings, Inc., is based in Warsaw, United States. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $132.673B | 26.23 |
| Medtronic (MDT) | Ireland | $124.635B | 18.20 |
| Stryker (SYK) | United States | $69.927B | 25.67 |
| Boston Scientific (BSX) | United States | $55.591B | 27.10 |
| Baxter (BAX) | United States | $39.448B | 24.31 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.755B | 0.00 |
| ResMed (RMD) | United States | $14.297B | 27.11 |
| Canopy Growth (CGC) | Canada | $10.742B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.172B | 52.25 |
| Aurora Cannabis (ACB) | Canada | $7.060B | 50.50 |
| Hill-Rom Holdings (HRC) | United States | $6.958B | 21.52 |
| Perrigo (PRGO) | Ireland | $6.649B | 10.09 |
| ICU Medical (ICUI) | United States | $5.184B | 28.88 |
| Insulet (PODD) | United States | $5.071B | 0.00 |
| Haemonetics (HAE) | United States | $4.540B | 40.28 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.400B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $3.380B | 0.00 |
| Hutchison China MediTech (HCM) | China | $3.329B | 0.00 |
| Neogen (NEOG) | United States | $3.267B | 50.18 |
| NuVasive (NUVA) | United States | $2.850B | 24.96 |
| Quidel (QDEL) | United States | $2.761B | 24.91 |
| National Vision Holdings (EYE) | United States | $2.637B | 51.01 |
| Aphria (APHA) | $2.539B | 112.78 | |
| NxStage Medical (NXTM) | United States | $2.000B | 0.00 |
| AtriCure (ATRC) | United States | $1.274B | 0.00 |
| HEXO (HEXO) | $1.242B | 0.00 | |
| Cardiovascular Systems (CSII) | United States | $1.240B | 890.25 |
| Phibro Animal Health (PAHC) | United States | $1.220B | 17.53 |
| VAREX IMAGING (VREX) | United States | $1.212B | 23.73 |
| MacroGenics (MGNX) | United States | $0.939B | 0.00 |
| Cerus (CERS) | United States | $0.904B | 0.00 |
| PetIQ (PETQ) | United States | $0.867B | 22.47 |
| Lantheus Holdings (LNTH) | United States | $0.847B | 22.95 |
| Surmodics (SRDX) | United States | $0.785B | 114.20 |
| Meridian Bioscience (VIVO) | United States | $0.733B | 21.85 |
| NanoString Technologies (NSTG) | United States | $0.721B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.720B | 31.76 |
| Omeros (OMER) | United States | $0.719B | 0.00 |
| Evolus (EOLS) | United States | $0.705B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.647B | 20.75 |
| LeMaitre Vascular (LMAT) | United States | $0.603B | 28.76 |
| Quanterix (QTRX) | United States | $0.518B | 0.00 |
| Insys Therapeutics (INSY) | United States | $0.426B | 0.00 |
| Owens & Minor (OMI) | United States | $0.408B | 5.65 |
| TG Therapeutics (TGTX) | United States | $0.398B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.339B | 21.99 |
| BioLife Solutions (BLFS) | United States | $0.329B | 445.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.294B | 0.00 |
| Vapotherm (VAPO) | United States | $0.288B | 0.00 |
| Bovie Medical (APYX) | United States | $0.282B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.262B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.256B | 0.00 |
| Zynex (ZYXI) | United States | $0.174B | 16.84 |
| Fonar (FONR) | United States | $0.144B | 7.70 |
| Surface Oncology (SURF) | United States | $0.140B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.112B | 0.00 |
| Chimerix (CMRX) | United States | $0.100B | 0.00 |
| United-Guardian (UG) | United States | $0.090B | 18.77 |
| Female Health (VERU) | United States | $0.084B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.078B | 0.00 |
| CAS Medical Systems (CASM) | United States | $0.070B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.066B | 18.20 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.057B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.056B | 0.00 |
| ImmuCell (ICCC) | United States | $0.038B | 0.00 |
| Neurotrope (NTRP) | United States | $0.034B | 0.00 |
| Senestech (SNES) | United States | $0.021B | 0.00 |
| Myomo (MYO) | United States | $0.016B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.014B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.014B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.013B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.010B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 14.14 |
